Sera Prognostics, which develops diagnostic tests for pregnancy complications, raised $75 million by offering 4.7 million shares at $16, within the range of $15 to $17.
Sera Prognostics uses its proprietary proteomics and bioinformatics platform to develop pregnancy and other women's health biomarker tests. The company's commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test that accurately predicts the risk of a premature delivery. The test is given to pregnant women during weeks 19 or 20 of gestation and provides a prediction of the mother's risk of delivering spontaneously before 37 weeks. The company reports that health insurance company Anthem (NYSE: ANTM) will make the PreTRM test available to eligible members as part of a multi-year contract.
Sera Prognostics plans to list on the Nasdaq under the symbol SERA. Citi, Cowen, and William Blair acted as joint bookrunners on the deal.
